

# SCIENTIFIC PROGRAMME

## PLENARY SESSIONS

### Wednesday 24 January

**14:00–14:30 Official Opening**

**14:35–15:45 State of the Art**

Chairpersons: Fortunato Ciardiello, Fred R. Hirsch, Filip Janků, Luboš Petruželka, Petra Tesařová

14:35–14:55 Fred R. Hirsch: Predictive biomarkers in the era of precision oncology

14:55–15:15 Fortunato Ciardiello: The past, present and future of CRC treatment

15:15–15:35 Filip Janků: Drugging undruggable: targeting Myc-driven cancers

15:35–15:45 Discussion

**15:45–16:00 Coffee Break**

**16:00–18:00 ASCO GI 2024, ESMO – hot news**

Chairpersons: Igor Kiss, Eugen Kubala, Radka Obermannová, Luboš Petruželka, Aleš Ryška, Jiří Tomášek

16:00–16:10 Luboš Petruželka: Pancreatic Cancer

16:10–16:20 Igor Kiss: Tumors of the Bile Ducts and Gallbladder

16:20–16:30 Radka Obermannová: Gastric Cancer

16:30–16:40 Eugen Kubala: Hepatocellular carcinoma

16:40–16:50 Jiří Tomášek: Neuroendocrine tumors

16:50–17:10 Luboš Petruželka: Colorectal Cancer, Conjugated monoclonal antibodies

17:10–17:30 Aleš Ryška: Conjugated monoclonal antibodies from a prediction perspective

17:30–18:00 Discussion

### Thursday 25 January

**8:30–10:00 Oncogynaecology**

Chairpersons: David Cibula, Ladislav Dušek, Daniela Fischerová, Roman Kocián, Jiří Sláma

8:30–8:45 Ladislav Dušek: The current state of screening and vaccination in the Czech Republic

8:45–9:00 Jiří Sláma: Why test for HPV in established cytological screening

9:00–9:15 Daniela Fischerová: The current standard in clinical staging

9:15–9:30 David Cibula: De-escalation of surgical treatment of early stages

9:30–9:45 Roman Kocián: Changing the standard of systemic treatment for advanced and metastatic illness

9:45–10:00 Discussion

**10:30–12:00 Breast Carcinoma**

Chairpersons: Zuzana Bielčíková, Pavel Dunder, Iveta Kolářová, Janina Kulka, Katarína Petráková, Lucie Reifová, Petra Tesařová, Bibiana Vertáková Krakovská

10:30–10:50 Janina Kulka: ER negative PR positive HER2 negative breast cancer is really rare

10:50–11:10 Bibiana Vertáková Krakovská: The possibility of stratification of the risk of recurrence of HR+HER2 negative breast carcinoma and indication of adjuvant treatment using CDK4/6

11:10–11:25 Pavel Dunder: Predictive testing in breast carcinoma

11:25–11:40 Iveta Kolářová: Collaboration between CCC and RCC – does it work?

11:40–12:00 Discussion

**12:00–13:00 Lunch Break**

**13:00–14:15 Localized Rectal Carcinoma**

Chairpersons: Soňa Argalacsová, Fortunato Ciardiello, Petr Dytrych, Tomáš Grega, Igor Kiss, Zdeněk Krška, Filip Pazdírek, Luboš Petruželka, Radek Pohnán, Pavel Šlampa, Milan Vošmik

13:00–13:20 Francesco Sclafani: Optimal management of locally advanced rectal cancer

13:20–14:15 Michal Vočka: Managed panel discussion with case study

**14:15–15:15 Subhepatic Space Carcinomas**

Chairpersons: Fortunato Ciardiello, Martin Doležal, Pavel Dundr, Tomáš Grega, Bohuslav Melichar, Radim Němeček, Luboš Petruželka, Gerald Prager, Jiří Tomášek, Michal Vočka

14:15–14:35 Gerald Prager: Metastatic pancreatic carcinoma - choosing the right first-line therapy

14:35–14:45 Panel discussion – chaired by Luboš Petruželka

14:45–15:00 Radim Němeček: Metastatic carcinoma of the gallbladder and bile ducts - choosing the right first-line therapy

15:00–15:15 Panel discussion – chaired by Luboš Petruželka, Michal Vočka

**16:30–17:30 Industry Symposium Janssen**

**Chair: prof. MUDr. Luboš Petruželka, CSc.**

Pavel Dundr: Practical aspects of testing patients with prostate and lung cancer in the Czech Republic

Gero Kramer: Genetics and its role in decision making process in patients with advanced prostate cancer

Leona Koubková: Personalized treatment through the eyes of a pneumonologist: immunotherapy or targeted therapy, how to decide?

**Friday 26 January**

**8:30–10:00 Urooncology**

Chairpersons: Marek Babjuk, Tomáš Büchler, Otakar Čapoun, Luboš Petruželka, Roman Zachoval

8:30–8:50 Gero Kramer: Standard of care for mHSPC: doublet or triplet?

8:50–9:05 Marek Svoboda: Genetic mutations in prostate carcinoma – epidemiology, diagnosis, prognostic impact

9:05–9:20 Štěpán Veselý: Prostate carcinoma in young men – risk of genetic predisposition and choice of local treatment

9:20–9:35 Martin Matějů: Advanced prostate carcinoma in patients with genetic predisposition

9:35–9:50 Tomáš Büchler: Neuroendocrine and non-secretory prostate carcinoma

09:50–10:00 Discussion

**10:00–10:30 Coffee Break**

**10:30–12:15 Hot News in Immunoncology and Precision Medicine**

Chairpersons: Peter Grell, Ľudmila Křížová, Luboš Petruželka, Miklos Pless, Jan Špaček, Radek Špišek, Juliane Walz

10:30–11:00 Juliane Walz: A new approach in immunoncology (peptide-based immunotherapies)

- 11:00–11:20 Radek Špíšek: The emerging role of interleukins in cancer – potential therapeutics targets?  
11:20–11:40 Peter Grell: HER2 as a tumour-agnostic biomarker  
11:40–12:05 Miklos Pless – A critical reading of a clinical trial in precision oncology (umbrella, basket, adaptive design trials)  
12:05–12:15 Discussion

**12:15–13:30 Lunch Break**

**13:30–15:00 Lung Carcinoma**

Chairpersons: Radovan Barila, Pavel Dundr, Mir Alireza Hoda, Robert Lischke, Luboš Petruželka, Jiří Votruba, Milada Zemanová, Petra Zemanová

- 13:30–13:40 Jiří Votruba: New imaging and biopsy techniques in the diagnosis of lung carcinoma  
13:40–13:55 Luboš Petruželka: Is neoadjuvant chemoimmunotherapy better than adjuvant immunotherapy?  
13:55–14:05 Robert Lischke: A surgical perspective on neoadjuvant treatment in non-small cell lung carcinoma  
14:05–14:20 Mir Alireza Hoda: Surgical options for locally advanced non-small cell lung cancer  
14:20–14:35 Radovan Barila: Innovations in targeted therapy for non-small cell lung carcinoma with activating mutations  
14:35–14:50 Pavel Dundr: Liquid biopsy in lung carcinoma  
14:50–15:00 Discussion on perspectives on the treatment of non-small cell lung carcinomas – chaired by Milada Zemanová

**15:00–15:15 Best Poster Prize**

**15:15 Official Closing**

**PARALLEL SESSIONS**

**Thursday 25 January**

- Diagnostics and HRD (homologous recombination deficiency) determination
- HER2-positive carcinoma in 2024 – amplification, overexpression, mutations (IHC, PCR NGS)
- MSI / MMRd IHC versus PRC versus NGS. What is the evidence and are there differences in diagnosis?
- Liquid biopsy and its utilization
- In 2024, NGS when and for whom?

**10:30–12:00 Basic Research in Oncology**

Chairpersons: Tomáš Eckschlager

- The study of specific mitochondrial metabolism in cancer cells
- Photodynamic therapy
- Sphingolipids in carcinogenesis
- AML patient-derived xenograft models
- Metabolism inducing chemoresistance in tumour cells

**09:00–14:50 Nursing Section**

**09:00–9:10 Opening**

**09:10–10:20 Block I**

Chairpersons: Dagmar Škočová, Jitka Němcová

- 9:10–9:30 Věra Melicherčíková: The decontamination of medical devices in the care of oncology patients
- 9:30–9:45 Lenka Křížanová: Preoperative indications in patients with gynaecological malignancies
- 9:45–10:00 Hana Janošková: The safe application of cytostatics in the 21st century
- 10:00–10:20 Marie Nejedlá: An interactive preventive programme focused on oncoprevention (including a practical demonstration)

**10:20–11:00 Coffee Break**

**11:00–12:15 Block II**

Chairpersons: Věra Melicherčíková, Šimíková

- 11:00–11:20 Irena Štenglová-Netíková: The administration of medication via nutrition tubes
- 11:20–11:40 Radkin Honzák: Spirituality, religiosity, prayer and medicine
- 11:40–11:55 Šárka Slavíková: Advocacy and the need for change in the social sphere
- 11:55–12:15 Matěj Hájek: The spiritual dimension of modern patient care

**12:15–13:15 Lunch**

**13:15–14:40 Block III**

Chairpersons: Marie Nejedlá, Hana Janošková

- 13:15–13:30 Lucie Müllerová: Social counselling in perinatal losses
- 13:30–13:50 Karel Nesměrák: From the history of antibiotics
- 13:50–14:10 Laura Janáčková: The fear of death
- 14:10–14:25 Eva Králová: Prophylaxis and healing of post-radiation reactions in brachytherapy of non-melanoma skin tumours
- 14:25–14:40 Marie Ředinová: The “Yes, we can” project
- 14:40–14:50 Discussion

**Friday 26 January**

**8:30–12:00 Key Advances in Oncological Research in the Czech Republic**

- Immunological configuration of ovarian carcinoma: the impact on disease outcome and response to immunotherapy
- Psychedelics in the treatment of existential distress in oncology patients
- Pharmacotherapy in tobacco cessation increases success
- Integromics tools for the prognosis and prediction of therapy outcome in ovarian carcinoma
- Use of the OnkoMonitor ctDNA test to monitor the effectiveness of treatment in patients with advanced solid tumours
- Radiosurgical treatment of brain metastases with CyberKnife Ostrava

**13:30–15:30 Neurooncology Session**

- The influence of mesenchymal cells on the presence and character of immune cells in a glioblastoma microenvironment
- The contribution of next-generation sequencing in the comprehensive management of gliomas – institutional experience
- High-grade gliomas as tumour duplications in patients with extracranial carcinomas – a retrospective multicentre study
- Seminoma metastasis in the brain
- Radiation-induced lymphopenia for the radiation of glioblastomas
- Herpetic encephalitis as a differential diagnosis for low-grade glioma
- SBRT treatment of osteosarcoma of the skull base

- Radiosurgical treatment of brain metastases
- The current Leksell Gamma Knife application in the treatment of brain metastases

**8:30–14:45 Palliative Session**

- 8:30–8:35 Opening
- 8:35–8:55 Lucie Lančová: Nuclear diagnostic methods hand in hand with therapy
- 8:55–9:15 Stanislav Hloušek: PSMA PET/CT – Radioligand therapy, new treatment options
- 9:15–9:40 Jolana Kopsa Těšínová: Legal aspects in practice when determining DNR and DNI
- 09:40–10:00 Discussion

**10:00–10:40 Break**

- 10:40–11:00 Zdeňka Pechačová: Combining modalities and the limits of radiotherapy in CNS and spinal tumours
- 11:00–11:25 Irena Štenglová-Netíková: The approach to changes in overall medication when ending targeted treatment from a pharmacologist's perspective
- 11:25–11:45 Ondřej Sláma: The renaissance of buprenorphine in cancer pain treatment
- TBA** Lohynská et al.: Commented poster on palliative RT for bladder cancer
- 11:50–12:00 Discussion

**12:00–13: 30 Lunch**

- 13:30–13:50 Jitka Fricová: Trends in breakthrough pain treatment
- 13:50–14:10 Jan Špaček: The toxicity of immunotherapy and treatment options
- 14:10–14:30 Karel Nesměrák: The history of vaccination
- 14:30–14:45 Discussion and conclusion